Sign in
4

Changes in Ownership

Rapport Therapeutics, Inc. Filed Acc 0001193125-26-154908

Chief Development Officer sold 19,865 shares at an average $35.03 ($695,823)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Yeleswaram Krishnaswamy · Chief Development Officer

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2026-04-10 Sale : show line 1 in the form 10b5-1 −500 $34.98 $17,490 286,016 D
2026-04-13 Sale : show line 2 in the form 10b5-1 −9,165 $34.97 $320,537 276,851 D
2026-04-14 Sale : show line 3 in the form 10b5-1 −10,200 $35.08 $357,797 266,651 D
Open-market sales · 19,865 sh · avg $35.03 · $695,823
Loading xslF345X06/ownership.xml…